Sorrento Therapeutics Inc (SRNE): Sorrento is exercising its option on MP1...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: None

Thursday, 08/26/2021 4:07:33 PM

Thursday, August 26, 2021 4:07:33 PM

Sorrento is exercising its option on MP18.
MPI8 demonstrated superior antiviral activity in a head-to-head comparison with a late-stage clinical antiviral compound (EIDD-2801).
Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.
EIDD-2801 is in a phase 2/3 study by Merck. The US government is committed to purchasing $1.2 billion worth of EIDD-2801 if the current trials are successful.
If MP18 is 3-10 times more effective what will it be worth?

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM